Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Isenberg

Showing results (31-40 of 280) with videos related to

Pageof 28
Sort By:
Acta Reumatologica Portuguesa|July 8, 2008
Novel therapies in lupus - focus on nephritisAna Cristina Cordeiro, David A Isenberg
Expert Review of Clinical Immunology|May 19, 2010
The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosusJessica J Manson, David A Isenberg
Clinical and Experimental Rheumatology|October 10, 2012
Outcome predictors in patients with idiopathic inflammatory myopathiesFernando B Salvador, David A Isenberg
Rheumatology (Oxford, England)|November 19, 2011
Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimenAmara N Ezeonyeji, David A Isenberg
Current Opinion in Hematology|May 16, 2009
mAbs in nonlupus autoimmune rheumatic diseaseBryan R Whelan, David A Isenberg
Clinical and Experimental Rheumatology|October 10, 2012
Use of autologous stem cell transplantation in adult patients with idiopathic inflammatory myopathies: a case-report and review of the literatureFernando B Salvador, David A Isenberg
Clinical and Experimental Rheumatology|September 21, 2013
Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathiesFrancisco Muñoz-Beamud, David A Isenberg
Expert Review of Clinical Immunology|January 21, 2016
Why, why, why de-lupus (does so badly in clinical trials)David A Isenberg, Joan T Merrill
Trends in Immunology|August 16, 2017
TRIM21 and the Function of Antibodies inside CellsDavid A Rhodes, David A Isenberg
Rheumatology (Oxford, England)|April 17, 2018
Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosusPedro L Carreira, David A Isenberg
Pageof 28

Showing results (31-40 of 280) with videos related to

Sort By:
Pageof 28
Acta Reumatologica Portuguesa|July 8, 2008
Novel therapies in lupus - focus on nephritisAna Cristina Cordeiro, David A Isenberg
Expert Review of Clinical Immunology|May 19, 2010
The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosusJessica J Manson, David A Isenberg
Clinical and Experimental Rheumatology|October 10, 2012
Outcome predictors in patients with idiopathic inflammatory myopathiesFernando B Salvador, David A Isenberg
Rheumatology (Oxford, England)|November 19, 2011
Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimenAmara N Ezeonyeji, David A Isenberg
Current Opinion in Hematology|May 16, 2009
mAbs in nonlupus autoimmune rheumatic diseaseBryan R Whelan, David A Isenberg
Clinical and Experimental Rheumatology|October 10, 2012
Use of autologous stem cell transplantation in adult patients with idiopathic inflammatory myopathies: a case-report and review of the literatureFernando B Salvador, David A Isenberg
Clinical and Experimental Rheumatology|September 21, 2013
Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathiesFrancisco Muñoz-Beamud, David A Isenberg
Expert Review of Clinical Immunology|January 21, 2016
Why, why, why de-lupus (does so badly in clinical trials)David A Isenberg, Joan T Merrill
Trends in Immunology|August 16, 2017
TRIM21 and the Function of Antibodies inside CellsDavid A Rhodes, David A Isenberg
Rheumatology (Oxford, England)|April 17, 2018
Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosusPedro L Carreira, David A Isenberg
Pageof 28